1
|
Rico-Fontalvo J, Morales-Portillo C, Bohórquez-Rivero J. En respuesta a: gliflozinas en el manejo de la enfermedad cardiovascular. Rev Colomb Nefrol 2023. [DOI: 10.22265/acnef.10.2.640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
Abstract
Hemos leído con gran interés el artículo de Braunwald E,1 titulado "Gliflozins in the management of cardiovascular disease" publicado recientemente en New England Journal of Medicine, donde el autor hace una excelente revisión de los inhibidores de SGLT2 (iSGLT2) y sus efectos a nivel cardiovascular; sin embargo, consideramos relevante aclarar ciertos puntos al respecto.
En Particular, cuando se mencionan los mecanismos de acción de estos fármacos a nivel renal, solo se incluyen los mecanismos hemodinámicos (natriuresis, disminución de la presión intraglomerular, glucosuria, restablecimiento de la retroalimentación túbulo-glomerular, entre otros) que, si bien son muy importantes, cabe agregar que existen mecanismos antiinflamatorios intrarrenales directos dados por la disminución de la glucotoxicidad renal (disminución de especies reactivas de oxígeno, moléculas proinflamatorias, miofibroblastos profibróticos, entre otros). Los efectos antiinflamatorios intrarrenales pueden explicar los efectos de estos fármacos a medio y largo plazo en términos de nefroprotección. En otras palabras, la inflamación juega un papel muy importante en el desarrollo de la enfermedad renal y los iSGLT2 tienen un impacto en estas vías, de ahí la importancia de abordar dichos mecanismos2.
La revisión también menciona que la dapagliflozina y la canaglifozina cuentan con la aprobación de la FDA para reducir el riesgo de enfermedad renal crónica en etapa terminal. Aclaramos que por el momento solo la dapagliflozina es la que cuenta con esta aprobación en base a la evidencia del estudio DAPA CKD3. Canagliflozina en su estudio CREDENCE solo incluyó pacientes con enfermedad renal diabética, por lo tanto, no tiene evidencia en enfermedad renal crónica no diabética4.
Collapse
|
2
|
Rodríguez de Vera-Gómez P, Mateo-Rodríguez C, Vivas-López C, Serrano-Olmedo I, Méndez-Muros M, Morales-Portillo C, Sevillano Jiménez M, Hernández-Herrero C, Martínez-Brocca MA. Effectiveness of a flash glucose monitoring systems implementation program through a group and telematic educational intervention in adults with type 1 diabetes. ENDOCRINOL DIAB NUTR 2022; 69:657-668. [PMID: 36424340 DOI: 10.1016/j.endien.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Accepted: 09/15/2021] [Indexed: 06/16/2023]
Abstract
OBJECTIVES Verifying the clinical effectiveness and the impact on quality-of-life parameters, fear of hypoglycaemia and satisfaction with the treatment obtained with a flash glucose monitoring (MFG) devices implantation program that includes a telematic and group educational intervention in adults with type 1 diabetes. PATIENTS AND METHODS Prospective quasi-experimental study, carried out during the COVID-19 pandemic period with a 9-month follow-up at the Virgen Macarena University Hospital, Sevilla. RESULTS Eighty-eight participants were included (men: 46.6%; mean age (years) 38.08, SD: 9.38); years of DM1 evolution: 18.4 (SD: 10.49); treatment with multiple doses insulin (MDI) 70.5% vs 29.5% subcutaneous insulin infusion therapy (CSII)). Baseline HbA1c was 7.74% (1.08). After the intervention, the global decrease in HbA1c was -0.45% (95% CI [-0.6, -0.25], P < 0.01), increasing to -1.08% in the group that started with HbA1c ≥ 8% (P < 0.01). A mean decrease in the Fear of Hypoglycemia 15 (FH15) test score of -6.5 points was observed (P < 0.01). In the global score of the Spanish version of Diabetes Quality Of Life (DQOL-s) test, the decrease was -8.44 points (P < 0.01). In Diabetes Treatment Satisfaction Questionnaire test (DTQ-s), global score increased in + 4 points (P < 0.01). CONCLUSIONS The incorporation of an educational program in group and telematic format within the development of MFG devices implantation strategies is an effective option, with associated benefits in quality of life and fear of hypoglycemia in adult patients with DM1. This option can be implemented in usual clinical practice.
Collapse
Affiliation(s)
| | - Carmen Mateo-Rodríguez
- Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - Carmen Vivas-López
- Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - Isabel Serrano-Olmedo
- Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - Mariola Méndez-Muros
- Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | | | - María Sevillano Jiménez
- Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | | | | |
Collapse
|
3
|
Rodríguez de Vera-Gómez P, Piñar-Gutiérrez A, Guerrero-Vázquez R, Bellido V, Morales-Portillo C, Sancho-Márquez MP, Espejo-García P, Gros-Herguido N, López-Gallardo G, Martínez-Brocca MA, Soto-Moreno A. Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice. J Diabetes Res 2022; 2022:4508633. [PMID: 36387939 PMCID: PMC9652069 DOI: 10.1155/2022/4508633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Revised: 09/01/2022] [Accepted: 10/19/2022] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVES The aim of this study is to investigate in depth diabetes mellitus associated with immune checkpoint inhibitors (DM-ICIs) by analysing a case series. We also evaluated the clinical impact of flash glucose monitoring (FGM) systems in the management of this entity. METHODS We conducted an observational cohort study of DM-ICIs diagnosed in two hospitals in Seville (Spain). Patients with a new diagnosis of diabetes mellitus (DM) or with sudden worsening of preexisting DM after starting treatment with ICIs, with a random 5 hour-postprandial C-peptide value of <0.6 nmol/L and without possibility of subsequent withdrawal of insulin treatment, were included. RESULTS A total of 7 cases were identified, mostly males (n = 6; 85.7%), with a mean age of 64.9 years. The mean glycated hemoglobin (HbA1c) upon diagnosis was 8.1%, with diabetic ketoacidosis (DKA) observed in 6 cases (85.7%). Subcutaneous flash glucose monitoring (FGM) systems were used in six cases, with a mean follow-up period of 42.7 weeks. During the first 90 days of use, mean average glucose was 167.5 mg/dL, with a coefficient of variation (CV) of 34.6%. The mean time in the range 70-180 mg/dL (TIR) was 59.7%, with a mean time above range (TAR) 181-250 mg/dL of 27.8% and a mean TAR > 250 mg/dL of 10.2%. The mean time below range (TBR) 54-69 mg/dL was 2%, while the mean TBR < 54 mg/dL was 0.3%. The mean glucose management indicator (GMI) was 7.3%. No significant differences were observed in FGM values for the following 90 days of follow-up. A progressive improvement in all parameters of glycaemic control was observed between the first month of FGM use and the sixth month of FGM use. Of note, there was a decrease in mean CV (40.6% to 34.1%, p = 0.25), mean TAR 181-250 (30.3% to 26%, p = 0.49), mean TAR > 250 mg/dL (16.3% to 7.7%, p = 0.09), mean TBR 54-69 mg/dL (5.2% to 2%, p = 0.16), and mean TBR < 54 mg/dL (1.8% to 0.2%, p = 0.31), along with an increase in mean values of TIR 70-180 mg/dL (46.5% to 60.5%, p = 0.09). The lack of statistical significance in the differences observed in the mean FGM values over the follow-up period may be related to the small sample size. CONCLUSION DM-ICI is recognised by a state of sudden-onset insulinopenia, often associated with DKA. The use of FGM systems may be a valid option for the effective management of DM-ICIs and for the prevention of severe hyperglycaemic and hypoglycaemic episodes in this condition.
Collapse
Affiliation(s)
| | - Ana Piñar-Gutiérrez
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Raquel Guerrero-Vázquez
- Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain
| | - Virginia Bellido
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | | | | | - Noelia Gros-Herguido
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Gema López-Gallardo
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | - Alfonso Soto-Moreno
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| |
Collapse
|
4
|
Rodríguez de Vera-Gómez P, Mateo-Rodríguez C, Vivas-López C, Serrano-Olmedo I, Méndez-Muros M, Morales-Portillo C, Sevillano Jiménez M, Hernández-Herrero C, Martínez-Brocca MA. Efectividad de un programa de implantación de sistemas de monitorización flash de glucosa a través de una intervención educativa grupal y telemática en adultos con diabetes tipo 1. ENDOCRINOL DIAB NUTR 2021. [DOI: 10.1016/j.endinu.2021.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Garrido-Hermosilla AM, Méndez-Muros M, Gutiérrez-Sánchez E, Morales-Portillo C, Díaz-Granda MJ, Esteban-González E, Relimpio-López I, Martínez-Brocca MA, Rodríguez-de-la-Rúa-Franch E. Renal function and choroidal thickness using swept-source optical coherence tomography in diabetic patients. Int J Ophthalmol 2019; 12:985-989. [PMID: 31236357 DOI: 10.18240/ijo.2019.06.17] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 11/26/2018] [Indexed: 11/23/2022] Open
Abstract
AIM To assess the relationship between choroidal thickness and renal function in diabetic patients. METHODS Cross-sectional retrospective clinical study of 42 eyes of 21 ocular treatment-naïve diabetic patients. Demographic data included: age, sex, type and course of diabetes. Ocular data included: severity of diabetic retinopathy; retinal thickness at the central macular region, as well as choroidal thickness at the central and paracentral quadrants, using automatically generated maps by swept-source optical coherence tomography; presence of cystic macular edema; and ocular axial length (AXL). Lab-test parameters included: glycated hemoglobin (HbA1c), albuminuria, albumin/creatinine ratio in urine, and glomerular filtration rate. RESULTS A significant negative correlation was mainly observed between several choroidal thicknesses, age (P<0.020) and ocular AXL (P<0.030). On the contrary, a significant positive correlation was found between all choroidal thicknesses, HbA1c (P<0.035) and albuminuria (P<0.040). CONCLUSION Choroidal thickness can represent an additional tool to help clinicians predicting the renal status in ocular treatment-naïve diabetic patients.
Collapse
Affiliation(s)
- Antonio Manuel Garrido-Hermosilla
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| | - Mariola Méndez-Muros
- Department of Endocrinology and Nutrition, Virgen Macarena University Hospital, Seville 41009, Spain
| | - Estanislao Gutiérrez-Sánchez
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| | | | - María Jesús Díaz-Granda
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| | - Eduardo Esteban-González
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| | - Isabel Relimpio-López
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| | | | - Enrique Rodríguez-de-la-Rúa-Franch
- Department of Ophthalmology, Virgen Macarena University Hospital, Seville 41009, Spain.,OftaRed, Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Arana C, Moreno-Fernández AM, Gómez-Moreno G, Morales-Portillo C, Serrano-Olmedo I, de la Cuesta Mayor MC, Martín Hernández T. Increased salivary oxidative stress parameters in patients with type 2 diabetes: Relation with periodontal disease. ACTA ACUST UNITED AC 2017; 64:258-264. [PMID: 28495321 DOI: 10.1016/j.endinu.2017.03.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2016] [Revised: 03/13/2017] [Accepted: 03/14/2017] [Indexed: 12/25/2022]
Abstract
OBJECTIVE The aim of this study was to determine whether there are differences in salivary oxidative stress between patients with diabetes mellitus type 2 (DM2) and healthy non-diabetic patients, and whether this oxidative stress is associated with the presence of periodontal disease in diabetic patients. MATERIAL AND METHODS This observational study included 70 patients divided into three groups according to metabolic control levels: 19 non-diabetic patients (control group); 24 patients with good metabolic control (HbA1c<7%), and 27 patients DM2 with poor metabolic control (HbA1c>7%). The following oxidative stress parameters were measured in all subjects: glutathione peroxidase (GPx), glutathione reductase (GRd), reduced glutathione (GSH) and oxidized glutathione (GSSG). Periodontal health was determined by means of the community periodontal index (CPI) recommended by the WHO. RESULTS The diabetic group with good metabolic control showed a significant increase in GPx and GRd activity in comparison with the control group (P<.001). The activity of the enzymes measured was significantly less in patients with poor metabolic control in comparison with the control group and well-controlled diabetic groups (P<.001). Both diabetic groups showed higher GSSG/GSH quotients and CPI in comparison with the control group, and both parameters were significantly higher in diabetic patients with poor metabolic control in comparison with well-controlled diabetic patients. CONCLUSIONS Poor metabolic control in DM2 patients is associated with higher levels of salivary oxidative stress and worse periodontal health.
Collapse
Affiliation(s)
- Carlos Arana
- Departamento de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, España.
| | - Ana María Moreno-Fernández
- Departamento de Citología e Histología Normal y Patológica, Facultad de Medicina, Universidad de Sevilla, Sevilla, España
| | - Gerardo Gómez-Moreno
- Departamento de Odontología en Pacientes Especiales, Grupo de Investigación Farmacológica en Odontología CTS-654 de la Junta de Andalucía, Facultad de Odontología, Universidad de Granada, Granada, España
| | | | - Isabel Serrano-Olmedo
- Departamento de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, España
| | | | - Tomás Martín Hernández
- Departamento de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, España
| |
Collapse
|